logo

Lupin Gets USFDA Nod for Generic Tablets To Treat Excessive Daytime Sleepiness

Authored By PTI | Last Modified: Aug 17, 2026 02:00 PM IST

Lupin Gets USFDA Nod for Generic Tablets To Treat Excessive Daytime Sleepiness
Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

New Delhi: Pharma major Lupin Ltd on Monday said it has received final approval from the US health regulator for the generic version of Pitolisant tablets indicated to treat excessive daytime sleepiness.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Pitolisant Tablets of strengths 4.45 mg and 17.8 mg, Lupin Ltd said in a regulatory filing.

The USFDA has approved Lupin’s Pitolisant tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix, the company said.

Wakix is a prescription medicine used to treat excessive daytime sleepiness (EDS) of Harmony Biosciences.

(Disclaimer: Except for the headline, this article has not been edited by HDFC Sky editorial team and is auto-generated from PTI feed.)

Disclaimer
At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Sector: Pharmaceuticals & Biotechnology

LUPIN Share Price

Lupin Ltd.

₹2,264.80

29.80(1.33%)
No Graph
1 Year Returns:-
17.35%
Desktop BannerMobile Banner
Invest Anytime, Anywhere
Play StoreApp Store
Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy